Search company, investor...

Predict your next investment

H.I.G. BioHealth Partners company logo
Venture Capital
FINANCE | Investment Firms & Funds
higbio.com

Investments

73

Portfolio Exits

15

Funds

1

Partners & Customers

1

About H.I.G. BioHealth Partners

H.I.G. BioHealth Partners invests in a broad range of life science opportunities across sectors and stages. The firm's seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. H.I.G. BioVentures invests in companies developing products for significant unmet medical needs, primarily in the following sectors: Therapeutics, Medical Devices, and Diagnostics.

Headquarters Location

1450 Brickell Avenue 31st Floor

Miami, Florida, 33131,

United States

305-379-2322

Want to inform investors similar to H.I.G. BioHealth Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest H.I.G. BioHealth Partners News

H.I.G. BioHealth Partners taps Watanabe as managing director

Mar 8, 2022

Previously, she worked at for Smith & Nephew’s U.S. robotics business unit where she was vice president and general manager. Email address I accept: Email address A link has been emailed to you - check your inbox. Sign in to your account Email address Nearly there! We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there. If you do not receive this within five minutes, please try and sign in again. If the problem persists, please email: subscriptions@peimedia.com. Copyright PEI Media Share with other subscribers Cancel

H.I.G. BioHealth Partners Investments

73 Investments

H.I.G. BioHealth Partners has made 73 investments. Their latest investment was in Click Therapeutics as part of their Series B on October 10, 2021.

CBI Logo

H.I.G. BioHealth Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/22/2021

Series B

Click Therapeutics

$52M

Yes

15

10/22/2020

Series A - IV

Orbus Therapeutics

$10M

No

1

8/11/2020

Series A - III

Orbus Therapeutics

$10M

No

1

7/20/2020

Series F - II

Subscribe to see more

$99M

Subscribe to see more

10

5/26/2020

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/22/2021

10/22/2020

8/11/2020

7/20/2020

5/26/2020

Round

Series B

Series A - IV

Series A - III

Series F - II

Series A - II

Company

Click Therapeutics

Orbus Therapeutics

Orbus Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$52M

$10M

$10M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

15

1

1

10

10

H.I.G. BioHealth Partners Portfolio Exits

15 Portfolio Exits

H.I.G. BioHealth Partners has 15 portfolio exits. Their latest portfolio exit was Clarus Therapeutics on September 09, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/9/2021

Reverse Merger

$99M

3

7/30/2021

IPO

$99M

Public

2

1/4/2021

Acquired

$99M

18

8/27/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/9/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/9/2021

7/30/2021

1/4/2021

8/27/2020

5/9/2019

Exit

Reverse Merger

IPO

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

3

2

18

10

10

H.I.G. BioHealth Partners Fund History

1 Fund History

H.I.G. BioHealth Partners has 1 fund, including H.I.G. BioHealth Partners III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/27/2019

H.I.G. BioHealth Partners III

$128.75M

1

Closing Date

11/27/2019

Fund

H.I.G. BioHealth Partners III

Fund Type

Status

Amount

$128.75M

Sources

1

H.I.G. BioHealth Partners Partners & Customers

1 Partners and customers

H.I.G. BioHealth Partners has 1 strategic partners and customers. H.I.G. BioHealth Partners recently partnered with Vertiflex on March 3, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

3/15/2017

Partner

United States

HIG BioHealth invests in VertiFlex

Michael Wasserman , HIG managing director , says : `` We are excited to partner with the VertiFlex management team .

1

Date

3/15/2017

Type

Partner

Business Partner

Country

United States

News Snippet

HIG BioHealth invests in VertiFlex

Michael Wasserman , HIG managing director , says : `` We are excited to partner with the VertiFlex management team .

Sources

1

H.I.G. BioHealth Partners Team

1 Team Member

H.I.G. BioHealth Partners has 1 team member, including current Managing Director, Michael Wasserman.

Name

Work History

Title

Status

Michael Wasserman

Managing Director

Current

Name

Michael Wasserman

Work History

Title

Managing Director

Status

Current

Compare H.I.G. BioHealth Partners to Competitors

A
Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

I
Informed Medical Communications

Informed Medical is an interactive medical information services provider that enables biopharmaceutical companies to market directly to physicians and patients.

C
CHALEX

Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.

Sage Science Logo
Sage Science

Sage Science develops products for the life sciences research markets. Its mission is to provide new systems to streamline and improve sample preparation workflows for DNA and protein analysis.

Punjab Biotechnology Incubator Logo
Punjab Biotechnology Incubator

Punjab Biotechnology Incubator (PBTI) welcomes users to its state-of-the- art Agri & Food Testing Laboratory set up at SAS Nagar (Mohali), the hub of Biotechnology and Information Technology in Punjab. PBTI is a State Govt. Undertaking registered as a "˜Society for Biotechnology Incubator' under the Society Registration Act 1961 and is professionally governed by Governing Council of the Society under the chairmanship of Chief Secretary, Govt. of Punjab. The day to day affairs are managed by Chief Executive Officer, supported by technical professionals of high caliber.

L
Laureate Pharma

Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.